Sugi Predict

Sugi Predict / Compounds / SCHEMBL4400427

SCHEMBL4400427

SCHEMBL4400427

O=C(Nc1ccc(F)cc1)C1(C(=O)Nc2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ RECQL P46063 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ RXFP1 Q9HBX9 1/20 0.64
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ LTA4H P09960 2/20 0.56
▸ AR P10275 1/20 0.54
▸ NR4A2 P43354 1/20 0.53
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ PTPN1 P18031 1/20 0.52
▸ PTPN6 P29350 1/20 0.52
▸ PTPN11 Q06124 1/20 0.52
▸ CASP3 P42574 1/20 0.52
▸ SENP8 Q96LD8 1/20 0.52
▸ SENP7 Q9BQF6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374030 0.90 MEN1 (0.56) MEN1KMT2AALDH1A1RECQLLMNA
SCHEMBL20216810 0.85 RAB9A (0.49) MEN1KMT2AALDH1A1RECQLLMNA
SCHEMBL13615636 0.85 MET (0.59) —
SCHEMBL28398157 0.84 MEN1 (0.52) MEN1KMT2AALDH1A1RECQLLMNA
SCHEMBL558092 0.82 POLB (0.55) MEN1KMT2ANPC1RAB9A
SCHEMBL1690825 0.81 MEN1 (0.69) MEN1KMT2AALDH1A1RECQLLMNA
SCHEMBL4405511 0.80 FAAH (0.66) —
SCHEMBL12468984 0.79 ALDH1A1 (0.53) KMT2AALDH1A1
SCHEMBL29548090 0.78 MET (0.66) —
SCHEMBL28808815 0.78 MEN1 (0.53) MEN1KMT2AALDH1A1RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-8476298-B2 c-Met modulators and method of use EXELIXIS, INC. (US) 2013-07-02 — — US disclosed
US-8178532-B2 c-Met modulators and method of use EXELIXIS, INC. (US) 2012-05-15 — — US disclosed
US-8067436-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2011-11-29 — — US disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 MEN1 1410/4885KMT2A 732/4885ALDH1A1 2597/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MEN1 1333/4885KMT2A 769/4885ALDH1A1 2578/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MEN1 1333/4885KMT2A 769/4885ALDH1A1 2578/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885ALDH1A1 2072/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 MEN1 1410/4885KMT2A 732/4885ALDH1A1 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.